07.10 14:30 | dpa-AFX: Regeneron Pharmaceuticals: IPR&D Charge To Negatively Impact Q3 EPS By Approx. $0.43 |
07.10 14:19 | dpa-AFX: *REGENERON ANTICIPATES $56 MLN ACQUIRED IN-PROCESS R&D CHARGE IN Q3 |
27.09 16:51 | dpa-AFX: Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment |
27.09 16:11 | Sanofi und Regeneron erhalten US-Zulassung für Dupixent bei COPD |
27.09 15:52 | dpa-AFX: *REGENERON & SANOFI : DUPIXENT APPROVED IN U.S. FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT |
27.09 13:36 | dpa-AFX: Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease |
27.09 13:05 | dpa-AFX: *REGENERON PHARMA AND SANOFI: NMPA IN CHINA APPROVES DUPIXENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
20.09 14:02 | dpa-AFX: *SANOFI: DUPIXENT RECOMMENDED BY CHMP FOR EU APPROVAL TO TREAT EOSINOPHILIC ESOPHAGITIS IN KIDS |
11.09 07:54 | Sanofi-Medikament Dupixent mit Studienerfolg bei Hautkrankheiten |
11.09 07:28 | dpa-AFX: Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints |
10.09 05:26 | dpa-AFX: Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC |
26.08 19:20 | MÄRKTE USA/Uneinheitlich - Technologiewerte mit Abgaben |
26.08 18:38 | MÄRKTE USA/Uneinheitlich - Technologiewerte mit Abgaben |
26.08 15:44 | MÄRKTE USA/Leicht positiv - Weitere US-Daten und Nvidia-Zahlen im Blick |
26.08 14:49 | MÄRKTE USA/Wenig verändert - Weitere US-Daten und Nvidia-Zahlen im Blick |
26.08 13:45 | dpa-AFX: Regeneron Pharma: European Commission Approves Ordspono |
26.08 13:17 | dpa-AFX: *REGENERON PHARMA: EC APPROVES ORDSPONO FOR TREATMENT OF R/R FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA |
26.08 07:03 | dpa-AFX: *REGENERON PHARMA TO PRESENT LATEST DUPIXENT AND ITEPEKIMAB DATA AT ERS |
21.08 03:23 | dpa-AFX: FDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple Myeloma |
05.08 06:00 | dpa-AFX: *RPT/DZ BANK RAISES FAIR VALUE FOR REGENERON TO 1218 (1065) USD - 'BUY' |
|